Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167777 | 0.86 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1148520 | 0.85 | MEN1 (0.32) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL4334790 | 0.83 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1149044 | 0.83 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL16401965 | 0.83 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL5564577 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL15569600 | 0.79 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL332512 | 0.78 | CA12 (0.36) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL319857 | 0.78 | MEN1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL3397667 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103793-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12565518-B2 | Hybrid cyclic libraries and screens thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4674416-A1 | PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION | NAGASAKI UNIVERSITY (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12508226-B2 | Lipid composition | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-12370143-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4328309-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565518-B2 | Hybrid cyclic libraries and screens thereof | NOLC1, BCL6, CHP1 | MEN1 2175/4885KMT2A 4074/4885HTT 4669/4885 |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | MEN1 2871/4885KMT2A 1594/4885HTT 2724/4885 |
| US-12370143-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | MEN1 4096/4885KMT2A 1797/4885HTT 781/4885 |
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | MEN1 4420/4885KMT2A 3081/4885HTT 3783/4885 |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | MEN1 3658/4885KMT2A 2382/4885HTT 1974/4885 |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | MEN1 2624/4885KMT2A 4263/4885HTT 1829/4885 |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | MEN1 1801/4885KMT2A 74/4885HTT 1991/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | MEN1 1859/4885KMT2A 1404/4885HTT 3451/4885 |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | MEN1 3203/4885KMT2A 4562/4885HTT 1084/4885 |
| US-12508226-B2 | Lipid composition | APOB, NAF1, SLC27A1 | MEN1 3062/4885KMT2A 2210/4885HTT 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.